Core Points - Rapid Dose Therapeutics Corp. has extended the maturity date of its secured convertible notes from November 30, 2025, to November 30, 2026 [1] - The financing involved the issuance of units at $1.00 per unit, which included $1.00 principal amount of notes convertible at $0.17 per share and five common share purchase warrants [2] - Noteholders holding $3,084,445 of notes agreed to the extension, while one noteholder with $50,000 opted for cash repayment [3] - The interest rate on the notes increased from 12% to 18% per annum, with interest payable quarterly in common shares [4] - The company issued 1,356,758 common shares to satisfy accrued interest of $62,860.65 on the notes [5] - The extension transaction involved insiders holding a total of $1,696,371 of notes and 8,481,855 warrants, qualifying as a related party transaction [7] Financing Details - The total principal amount of notes issued during the financing was $3,134,445, along with 15,672,225 warrants [2] - The exercise price for the extended warrants is set at $0.16, with the expiry date also extended to November 30, 2026 [3] - The company is allowed to prepay the notes with a 10-day advance notice [4] Company Overview - Rapid Dose Therapeutics is a Canadian biotechnology company focused on innovative drug delivery solutions [8] - The flagship product, QuickStrip™, is an orally dissolvable film that can deliver various active ingredients rapidly into the bloodstream [8]

Core Viewpoint - Rapid Dose Therapeutics Corp. intends to extend the maturity date of its outstanding secured convertible notes from November 30, 2025, to November 30, 2026, as part of a strategic financial maneuver to manage its debt obligations [1]. Financing Details - The financing involved an offering of units priced at $1.00 per unit, each consisting of $1.00 principal amount of notes convertible at $0.17 per share, along with five common share purchase warrants with an exercise price between $0.14 and $0.17 per share, expiring on November 30, 2025. The total principal amount of notes issued was $3,134,445, along with 15,672,225 warrants [2]. Extension Agreement - Noteholders holding $3,084,445 of notes have agreed to extend the maturity date and the expiry date of their accompanying warrants to November 30, 2026, with an adjusted exercise price of $0.16. An extension fee of 5% will be paid in common shares at a price of $0.16 per share. One noteholder with a $50,000 note will receive cash repayment instead of an extension [3]. Interest Rate Adjustment - The interest rate on the notes will increase from 12% to 18% per annum, calculated and compounded monthly, with interest payable quarterly in arrears in common shares based on the closing market price on the Canadian Securities Exchange [4]. Accrued Interest Payment - The company plans to issue common shares to satisfy accrued and unpaid interest totaling $62,860.65 on the notes, due on the initial maturity date of November 30, 2025. This issuance is expected to occur no later than December 15, 2025 [5]. Securities Hold Period - All securities issued under the extension and for the payment of accrued interest will be subject to a hold period of four months and one day from the date of issuance [6]. Insider Participation - Certain insiders hold a total of $1,696,371 of notes and participated in the extension. The company is relying on exemptions from valuation and minority shareholder approval requirements due to the nature of the transaction being within the related party context [7]. Company Overview - Rapid Dose Therapeutics is a Canadian biotechnology company focused on innovative drug delivery solutions, with its flagship product QuickStrip™, an orally dissolvable film that can deliver various active ingredients rapidly into the bloodstream [8].

Core Points - Rapid Dose Therapeutics Corp. plans to issue common shares to satisfy accrued interest on secured convertible notes by October 15, 2025 [1][4] - The financing involved units priced at $1.00 each, consisting of notes and warrants, totaling $3,134,445 in notes and 15,672,225 warrants issued in 2023 [2] - The notes have a maturity date of November 30, 2025, with a 12.0% annual interest rate, payable quarterly in common shares [3] Financial Details - The company will issue 592,533 common shares at a deemed price of $0.16 per share to cover $94,806.23 of accrued interest [4] - All common shares issued for interest payments will have a hold period of four months and one day from the issuance date [5] Company Overview - Rapid Dose Therapeutics is a Canadian biotechnology firm focused on innovative drug delivery, with its flagship product QuickStrip™, an orally dissolvable film for rapid delivery of various active ingredients [6]